Approved HIV reverse transcriptase inhibitors in the past decade

Autor: Erik De Clercq, Guangdi Li, Yali Wang

Publikováno v: Acta Pharmaceutica Sinica B. 12:1567-1590

HIV reverse transcriptase (RT) inhibitors are the important components of highly active antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in clinical practice. Many RT inhibitors and their combination regimens have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef424a5c6c813905e85108700bf093a5
https://doi.org/10.1016/j.apsb.2021.11.009

Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

Autor: George V. Papatheodoridis, Harry L.A. Janssen, Florian van Boemmel, Margarita Papatheodoridi, Anastasia Kourikou, Cihan Yurdaydin, Bettina E. Hansen, Pietro Lampertico, John Vlachogiannakos, Ramazan Idilman, Savvoula Savvidou, John Goulis, Marta López-Gómez, Spilios Manolakopoulos, Thomas Berg, Nikolaos K. Gatselis, Maria Buti, Jose Luis Calleja, Rafael Esteban, George N Dalekos, Rhea Veelken, Vana Sypsa, Kostas Galanis, Alessandro Loglio

Publikováno v: JHEP Reports
JHEP Reports, Vol 3, Iss 3, Pp 100290-(2021)
Scientia
JHEP Reports, 3(3):100290. Elsevier

Background & Aims Recently, several risk scores for prediction of hepatocellular carcinoma (HCC) were developed in cohorts of treated Asian patients with chronic hepatitis B (CHB), but they have not been assessed in non-Asian patients. We evaluated t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b54bf4ed65b784ec4c4c4980026192f
https://pure.eur.nl/en/publications/eaca8f96-a655-49b8-b491-412854979fbb

Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC

Autor: Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Hye Won Lee, Terry Cheuk-Fung Yip, Stephen L. Chan, Lilian Yan Liang, Hester Wing-Sum Luk, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Yee-Kit Tse, Becky Wing-Yan Yuen

Publikováno v: JHEP Reports
JHEP Reports, Vol 2, Iss 6, Pp 100152-(2020)

Background & Aims Antiviral treatment is known to improve survival in patients with chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC). Yet, the treatment uptake in CHB patients remains low. We aimed to report the secular trend in antiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d8b7f794f020941cbb37b15cf5773b
https://pubmed.ncbi.nlm.nih.gov/33024950

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells.

Autor: Aggarwal A; Gilead Sciences, Foster City, CA, USA., Odorizzi PM; Gilead Sciences, Foster City, CA, USA., Brodbeck J; Gilead Sciences, Foster City, CA, USA., van Buuren N; Gilead Sciences, Foster City, CA, USA., Moon C; Gilead Sciences, Foster City, CA, USA., Chang S; Gilead Sciences, Foster City, CA, USA., Adona M; Gilead Sciences, Foster City, CA, USA., Suthram S; Gilead Sciences, Foster City, CA, USA., Suri V; Gilead Sciences, Foster City, CA, USA., Trowe T; Gilead Sciences, Foster City, CA, USA., Turner S; Gilead Sciences, Foster City, CA, USA., Marcellin P; Hôpital Beaujon, Clichy, France., Buti M; Hospital Universitario Valle Hebron, Barcelona, Spain., Gaggar A; Gilead Sciences, Foster City, CA, USA., Fletcher SP; Gilead Sciences, Foster City, CA, USA., Diehl L; Gilead Sciences, Foster City, CA, USA., Feierbach B; Gilead Sciences, Foster City, CA, USA., Balsitis S; Gilead Sciences, Foster City, CA, USA.

Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2022 Dec 26; Vol. 5 (4), pp. 100664. Date of Electronic Publication: 2022 Dec 26 (Print Publication: 2023).